Oncternal Therapeutics Inc (ONCT) Stock
ONCT is no longer traded. Oncternal Therapeutics was delisted from the Nasdaq in December 2024.
Prices on this page are historical; the last trade was December 2, 2024 at $0.53.
Oncternal Therapeutics stock price history
ONCT final trading statistics
- Final close
- $0.53
- Final trading day
- Dec 2, 2024
- Market cap at delisting
- $1.57M
- Shares outstanding
- 2.96M
- Final 52-week range
- $0.31 – $10.61
- Avg. volume (final 3 mo.)
- 138,718
- All-time high (split-adj.)
- $32732.00 · Apr 2007
- All-time low (split-adj.)
- $0.53 · Dec 2024
- Return since IPO
- -100.0%
- Beta
- 1.33
- Book value / share
- $3.09
- Price / book
- 0.17
Oncternal Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $785.0K | -$39.5M | -$3.63 |
| FY2022 | $1.49M | -$43.4M | -$0.84 |
| FY2021 | $4.32M | -$31.3M | -$0.63 |
| FY2020 | $3.38M | -$17.2M | -$0.96 |
| FY2019 | $2.42M | -$15.9M | -$4.21 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Oncternal Therapeutics stock FAQ
What happened to Oncternal Therapeutics stock?
Oncternal Therapeutics stock was delisted from the Nasdaq. Its final close was $0.53 on December 2, 2024.
Is ONCT stock still trading?
No. ONCT was delisted from the Nasdaq in December 2024 and no longer trades on a U.S. exchange.
What was the last price of ONCT stock?
ONCT closed at $0.53 on its final trading day, December 2, 2024, for a market value of about $1.57M.
What were Oncternal Therapeutics's revenue and earnings in its last full fiscal year?
Oncternal Therapeutics reported revenue of $785.0K and net income of -$39.5M in fiscal 2023, its last full year as a public company.
When did Oncternal Therapeutics go public?
Oncternal Therapeutics Inc stock began trading on February 3, 2004.